Beijing Pearl Biotechnology Limited Liability Company Report issue

Government Phase 1 Phase 3

Organization Overview

First Clinical Trial
2016
NCT02896231
First Marketed Drug
2021
fluvastatin (lescol)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

BEIJING | Beijing Pearl Biotechnology Limited Liability Company

Active Ingredients

Marketed Drugs (3)

fluvastatin (lescol) (2021)

foscarnet (foscavir) (2023)

niacin (2021)

Drugs in Phase 3 Trials (4)

cisplatin (platinol) (1 trial)

etoposide (vepesid) (1 trial)

plb1001 (5 trials)

temozolomide (temodar) (1 trial)

Drugs in Phase 1 Trials (1)

plb1003 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Glioma (Phase 1)

Lung Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 5